Eli Lilly Acquires Calyonia Pharmaceuticals for $7 Billion
Eli Lilly has announced its acquisition of Calyonia Pharmaceuticals in a deal valued at $7 billion. The agreement includes an upfront payment of $3.25 billion, with additional payments contingent on achieving clinical, regulatory, and commercial milestones.